Enhanced Vascular Inflammation in Advanced Prostate Cancer Patients Undergoing Hormone Therapy
Abstract
Advanced PCa patients undergoing hormone therapy demonstrate increased arterial inflammation on [<sup>18</sup>F]FDG-PET imaging compared to non-hormonally treated controls. These findings support a possible mechanistic link between hormone therapy and the elevated cardiovascular risk observed in this patient population.
Introduction
Androgen deprivation therapy (ADT) and androgen receptor pathway inhibitors (ARPIs) are cornerstones in the management of advanced prostate cancer (PCa). While these therapies significantly improve oncological outcomes by suppressing androgen-driven tumor growth, they are associated with a well-documented increase in cardiovascular (CV) morbidity and mortality. The underlying biological mechanisms linking hormone therapy to CV events like myocardial infarction and stroke remain partially understood, though chronic vascular inflammation—a precursor to atherosclerosis—is a leading hypothesis. This study investigates whether [<sup>18</sup>F]FDG-PET/CT imaging can detect and quantify this inflammation in vivo.
Methods
The researchers conducted a retrospective cohort study at Vienna General Hospital, analyzing 49 patients with metastatic PCa. The cohort was divided into two groups: Cohort A (n=32), consisting of patients actively receiving hormone therapy (ADT or ARPI), and Cohort B (n=17), a control group of patients who had not received such therapy for at least 12 months.
All participants underwent whole-body [<sup>18</sup>F]FDG-PET/CT scans. To quantify vascular inflammation, Regions of Interest (ROIs) were manually delineated on the arterial walls of the abdominal aorta, ascending aorta, aortic arch, thoracic descending aorta, and carotid arteries. Metabolic activity was measured using the Standardized Uptake Value (SUV). To account for background blood-pool activity, the Target-to-Background Ratio (TBR) was calculated by normalizing arterial SUV against the activity in the superior vena cava. Additionally, a semi-quantitative Calcified Plaque (CP) score (0–4) was derived from CT data to assess structural arterial damage.
Key Results
The study revealed a significant increase in arterial FDG uptake among patients receiving hormone therapy. Specifically, the maximum Target-to-Background Ratio (TBRmax) was significantly higher in the hormone therapy group across multiple segments:
- Abdominal aorta: median 1.6 vs. 1.4 (p=0.007)
- Ascending aorta: 1.6 vs. 1.4 (p=0.026)
- Thoracic descending aorta: 1.6 vs. 1.4 (p=0.035)
- Combined arterial analysis: 1.6 vs. 1.4 (p=0.006)
Importantly, there were no significant differences between the two cohorts regarding calcified plaque (CP) scores, age, BMI, or traditional CV risk factors such as LDL cholesterol and C-reactive protein (CRP). Furthermore, FDG uptake in the spleen and bone marrow was comparable between groups, suggesting that the observed inflammation was localized to the vasculature rather than being a manifestation of systemic immune activation.
Discussion
These findings provide direct evidence that hormone therapy in PCa patients is associated with increased active vascular inflammation. The lack of difference in CP scores suggests that the therapy drives dynamic, metabolic changes in the arterial wall—potentially early-stage atherosclerotic processes—rather than simply correlating with pre-existing calcified disease.
From a clinical perspective, this study underscores the potential for "opportunistic screening." As [<sup>18</sup>F]FDG-PET/CT is increasingly utilized in advanced PCa to identify aggressive phenotypes (often in tandem with PSMA-PET), the same imaging data can be analyzed to monitor cardiovascular risk. This dual-purpose approach could facilitate early intervention and personalized CV risk management without additional radiation exposure or cost.
Conclusion
Hormone therapy for advanced prostate cancer is linked to significantly higher levels of arterial inflammation, detectable via [<sup>18</sup>F]FDG-PET imaging. While limited by its retrospective and cross-sectional nature, this study identifies a potential mechanistic bridge between cancer treatment and cardiovascular risk. Future prospective, longitudinal studies are warranted to determine if these imaging biomarkers can predict future cardiovascular events and to evaluate the impact of cardioprotective interventions in this high-risk population.
Summary updated